This is an international site for AFINITOR® (everolimus) and is intended for Health Care Professionals outside the U.S. The information on the site is not country-specific, and may contain information that is outside the approved indications in the country in which you are located. Please contact your local Novartis representative for the latest information specific to your country

I am a healthcare professional outside of the US I am a US Resident I am a patient outside of the US

AFINITOR® (everolimus) Logo | AFINITOR.com
AFINITOR is a once-daily oral inhibitor of mTOR (mammalian target of rapamycin) for patients with advanced renal cell carcinoma (RCC) whose disease has progressed on or after treatment with VEGF-targeted therapy
Afinitor now approved in the EU!
Afinitor International Website  |  For Healthcare Professionals Outside the U.S.  |  US Residents

Stay informed on the latest information, including news related to AFINITOR and other updates.

Register for Afinitor Updates
Afinitor Approved Countries

Thank You for Sharing AFINITOR.com With a Colleague

After clicking the send button below, your colleague will receive an e-mail from you containing an Internet link to this page.

All fields are required.

Your Name
Your E-mail
Colleague's E-mail

The e-mail addresses you furnish will be used solely to notify the recipient of the link to this page and that you have requested it be sent. The addresses will not be retained or reused. Learn more about our Privacy Policy.